A retrospective study assessing the efficacy of Bictegravir/emtricitabine/tenofovir-alafenamide in patients with NRTI RAMs identified by routine genotypic resistance testing in patients living with HIV infection
Latest Information Update: 29 Mar 2023
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Therapeutic Use
Most Recent Events
- 01 Mar 2023 Results published in the HIV Medicine
- 01 Sep 2021 New trial record
- 21 Jul 2021 Results presented at the 11th International AIDS Society Conference on HIV Science